Surajit Pal, pharma analyst, Prabhudas Lilladher, says receivables of Indian companies from Venezuel will be Impacted in case of currency devaluation.
“Dr Reddy's revenue from Venezuela was at USD 13.7 crore in FY15 and overall USD 3 crore exposures in receivables are always maintained. Similarly, for Glenmark, the receivables exposure is around USD 2.0-2.2 crore. In the worst case scenario, the EPS impact for DRL will be around Rs 5 and Rs 3 for Glenmark”, said Surajit.
Praful Bohra, VP-Research, Religare, however, has a different opinion on Glenmark. Bohra believes the negatives on the Venezuelan exposure have already been factored into estimates.
Glenmark has already stopped producing much for the Venezuelan market over last 2 quarter and this is visible from their limited receivables exposure, he said, adding that he does not expect any large incremental negative.
“Glenmark has been booking sales at average rate of 15-16 bolivar per dollar, so their rate is already higher than official rate of 5-6 bolivar, which limits the impact” he said.
Religare does not have coverage on DRL.
Exclusive offer: Use code "BUDGET2020" and get Moneycontrol Pro's Subscription for as little as Rs 333/- for the first year.